摘要
目的:探讨血清肿瘤相关糖类抗原19-9(CA19-9)在消化道疾病中的临床意义。方法:应用化学 发光免疫分析检测47例消化道恶性肿瘤患者(恶性组)、46例消化道良性疾病患者(良性组)和49例健康人 (对照组)血清中CA19-9。结果:在恶性组的47例、良性组的46例和对照组的49例血清样品中,CA19-9平 均水平分别为263.4±259.9、47.4±43.3和15.5±9.2U/ml,恶性组的CA19-9平均水平与良性组比较显著 升高(P<0.001);良性组的CA19-9平均水平与对照组比较显著升高(P<0.005)。结论:在消化道疾病中, 无论良恶性其血清CA19-9均可有不同程度的增高,结合影像学对CA19-9增高可作进一步判断。
Objective To investigate the clinical significance of determination of serum tumor marker CA19-9 levels in patients with digestive tract diseases. Methods Serum CA19-9 levels were determined with CELIA in 93 patients with digestive tract diseases (benign 46, malignant 47) and 49 controls. Results Serum CA19-9 levels in patients with malignant digestive tract diseases (263.4±259.9U/ml) were significantly higher than those in patients with benign diseases (67.5±127.0U/ml) (P<0.001). Also, the levels in patients with benign digestive tract diseases were significantly higher than those in controls (15.5±9.2U/ml) (P<0.005). Conclusion Serum CA19-9 levels were elevated in patients with either malignant or benign digestive tract disease. Definite diagnosis might be obtained with further imaging studies.
出处
《放射免疫学杂志》
CAS
2005年第1期67-69,共3页
Journal of Radioimmanology
